SCHEMBL10102678

SCHEMBL10102678

CNCCCc1cc2cc(C(C)(C)C)ccc2nc1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
PDE10A Q9Y233 1/20 0.37
PTGFR P43088 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR1A P08908 1/20 0.36
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
PSMB5 P28074 1/20 0.34
KDM4E B2RXH2 3/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MTNR1A P48039 2/20 0.34
MTNR1B P49286 2/20 0.34
CTSK P43235 1/20 0.34
KCNH2 Q12809 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102677 0.85 VSIR (0.38) AKT1AKT2PTGFRMEN1KMT2A
SCHEMBL13005210 0.85 AKT1 (0.39) AKT1AKT2PDE10APTGFRKMT2A
SCHEMBL10102675 0.84 PSMB5 (0.43) AKT1AKT2PDE10AHTR1DPSMB5
SCHEMBL10102667 0.82 PSMB5 (0.43) PDE10APTGFRMEN1KMT2APSMB5
SCHEMBL13005203 0.77 AKT1 (0.36) AKT1AKT2PDE10APTGFRPSMB5
SCHEMBL10102676 0.76 DHODH (0.40) PTGFRKDM4EGAAALDH1A1MTNR1A
SCHEMBL3386183 0.74 PIK3CG (0.40) SMN1; SMN2ALDH1A1HPGD
SCHEMBL10102655 0.74 PDE4B (0.37) KDM4ESMN1; SMN2
SCHEMBL3383001 0.73 DHODH (0.45) KMT2AKDM4ECTSKKCNH2RXRA
SCHEMBL10102645 0.71 CNR2 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B AKT1 1807/4885AKT2 1838/4885PDE10A 4376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.